Atazanavir
- Generic Name
- Atazanavir
- Brand Names
- Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C38H52N6O7
- CAS Number
- 198904-31-3
- Unique Ingredient Identifier
- QZU4H47A3S
- Background
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
- Indication
Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT02566707
- Locations
- 🇳🇱
St. Elisabeth, Tilburg, Netherlands
🇳🇱Rijstate, Arnhem, Netherlands
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- Conditions
- Hepatitis CHIV
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02565888
- Locations
- 🇳🇱
CRCN, Radboud University Medical Center, Nijmegen, Netherlands
A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Castagna Antonella
- Target Recruit Count
- 10
- Registration Number
- NCT02542852
- Locations
- 🇮🇹
Ospedale San Raffaele Scientific Institute, Milan, Italy
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
- Target Recruit Count
- 90
- Registration Number
- NCT02473328
- Locations
- 🇫🇷
DUDOIT Yasmine, Paris, France
Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 86
- Registration Number
- NCT02386098
- Locations
- 🇹🇭
GSK Investigational Site, Bangkok, Thailand
Taste Properties of Atazanavir and Cobicistat
- Conditions
- HIV in Adults
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT02307656
- Locations
- 🇺🇸
Senopsys Llc, Woburn, Massachusetts, United States
Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT02257008
Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT02253836
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02116660
ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 300
- Registration Number
- NCT02102048
- Locations
- 🇮🇹
Department of Public Heath and Infectious Diseases. University of Rome "Sapienza" (Italy), Rome, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.